| Autor: |
Meiyi Xu, Tianhao Shi, Ruilian Xu, Gong Chen, Wan He |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Journal of the National Cancer Center, Vol 3, Iss 3, Pp 203-210 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2667-0054 |
| DOI: |
10.1016/j.jncc.2023.05.005 |
| Popis: |
Detection of minimal/molecular residual disease (MRD) based on ctDNA assay develops from hematological malignancies to solid tumors. Generally, there are two mainstream assays in MRD testing technology: tumor-informed and tumor-agnostic. For colorectal cancer (CRC), MRD is used not only to monitor recurrence and predict prognosis, but also to help in clinical decision making and assessment of clinical efficacy in the settings of curative surgery, radiotherapy, chemotherapy and surveillance. Accumulated clinical trials are exploring roles of MRD in early or advanced stages of CRC. Here, we give an overview of how MRD is and will be used in CRC. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
